News & Events

At Gondola Medical Technologies, we have observed that dual-tasking is a real challenge for many patients with neurological disorders like Parkinson’s Disease (PD). The ability to walk while simultaneously talking or thinking…

Gondola Medical Technologies first launched the Gondola AMPS therapy for people with walking and balancing impairment due to neurological disorders in 2011. Since then, the company has successfully supported many Parkinson’s Disease…

Gondola Medical Technologies is excited to announce that Alain Coudray has joined the board of directors. As the company is heading towards many exciting milestones, including a market entry in Germany and…

In the MedTech industry, scientific evidence is essential to be authorized for use by regulatory bodies and to gain support from medical professionals. Biomechanics, the study of the movements and structures of…

The AMBITION clinical trial aims to investigate the safety and efficacy of the Gondola AMPS therapy in 40 Parkinson’s disease patients suffering from severe freezing of gait (FOG) symptoms, despite dopaminergic and deep brain stimulation (DBS) treatments. It is a particularly interesting population to use the Gondola AMPS therapy, as there are limited treatment options for FOG treatment

A large meta-analysis published last year (Zhang et al, 2021) reported that more than half of patients with Parkinson’s Disease experience, more or less regularly, episodes of Freezing Of Gait (FOG). FOG…

Clinical research and studies demonstrate Gondola AMPS therapy’s effectiveness for people with neurological disease to move better and live better. The CHF 500’000 Tech Growth loan from the Fondation pour l’Innovation Technologique…

Gait disturbances in Parkinson’s disease and parkinsonism, also called parkinsonian gait, worsen the risk of falling and directly impact life quality. Parkinsonian gait is a complex combination of multiple factors. At Gondola…

If you have any questions about the science behind the Gondola AMPS therapy, get in touch with our clinical team. They are happy to discuss academic and clinical research collaborations along with questions about our past and future research. They are passionate about explaining the Gondola AMPS mechanism of action and how the therapy manages to achieve a remarkable clinical effect. Also, any neuroscience questions and interest in the AMPS therapy treatment plan are welcome. The clinical team at Gondola Medical Technologies currently consists of three team members, Shannon Edd, Ph.D., Clinical Research Manager, Tiffany Corbet, PT, Ph.D., and Clinical Field Scientist Paul Alouani, MSc, Clinical Research Associate.

Reduced access to healthcare Since the beginning of the COVID crisis, European countries have adopted unprecedented measures to counter the pandemic. These measures come with significant consequences on society, everyday life, and…